Products - Metastases | Topic | NICE

Showing 8 products

Date | Title

Status: PublishedRemove ‘Status: Published’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Product type:
Guidance
Programme:
Technology appraisal guidance
Expected publication date:
15 June 2022
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation) (TA1179)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 July 2026
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (TA1174)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 July 2026
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer (TA1150)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 May 2026
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal) (TA1141)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 March 2026
Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 February 2026
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer (TA1130)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 February 2026
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer (TA1122)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 January 2026